Is BioAge Labs, Inc. (BIOA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.0% / 30% | 41.8% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 1.0% / 33% | 41.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 2.4% / 33% | 98.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 1.0% / 33% | 41.8% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 2.4% / 33% | 98.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -923.4% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -27.1% | |
| Return on Assets (ROA) | -17.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$52M |
| Free Cash Flow | -$52M |
| Total Debt | $9M |
| Debt-to-Equity | 2.0 |
| Current Ratio | 14.2 |
| Total Assets | $358M |
Price & Trading
| Last Close | $16.25 |
| 50-Day MA | $19.92 |
| 200-Day MA | $10.33 |
| Avg Volume | 726K |
|
52-Week Range
$2.88
| |
About BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BioAge Labs, Inc. (BIOA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BioAge Labs, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BioAge Labs, Inc.'s debt ratio?
BioAge Labs, Inc.'s debt ratio is 1.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 2.4%.
What are BioAge Labs, Inc.'s key financial metrics?
BioAge Labs, Inc. has a market capitalization of $717M. Return on equity stands at -27.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.